Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors. - Wikidata - awgldk - TriplyDB

Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors.

Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors.

http://www.wikidata.org/entity/Q42162649

about

Management of Ewing sarcoma family of tumors: Current scenario and unmet need Diagnosis and treatment of Ewing sarcoma of the bone: a review article Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Phase II study of cisplatin and oral VP16 in patients with refractory or relapsed Ewing sarcoma.Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors.Treatment pathway of bone sarcoma in children, adolescents, and young adults A study of docetaxel and irinotecan in children and young adults with recurrent or refractory Ewing sarcoma family of tumors.Current therapeutic approaches in metastatic and recurrent ewing sarcoma Camptothecin-based regimens for treatment of ewing sarcoma: past studies and future directions Metastatic Ewing's sarcoma/PNET of kidney in 40 year old patient Molecular pathogenesis and targeted therapeutics in Ewing sarcoma/primitive neuroectodermal tumours.Endoplasmic reticulum targeting in Ewing's sarcoma by the alkylphospholipid analog edelfosine Targeted therapy in Ewing sarcoma.Treating metastatic soft-tissue or bone sarcomas - potential role of ridaforolimus.Advances in paediatric cancer treatment EWING'S SARCOMA: EPIDEMIOLOGY AND PROGNOSIS FOR PATIENTS TREATED AT THE PEDIATRIC ONCOLOGY INSTITUTE, IOP-GRAACC-UNIFESP Pilot Study of Adding Vincristine, Topotecan, and Cyclophosphamide to Interval-Compressed Chemotherapy in Newly Diagnosed Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology Group A phase I/II study of CY and topotecan in patients with high-risk malignancies undergoing autologous hematopoietic cell transplantation: the St Jude long-term follow-up An Unusual Location of Extraosseous Ewing's Sarcoma.Expanded Access Through Cancer Trials Support Unit to Children's Oncology Group Sarcoma Trial AEWS1031 for Adolescents and Young Adults Pharmacotherapy of sarcoma.Sarcomas gone bad: what to do about recurrent Ewing sarcoma.Ewing sarcoma: clinical state-of-the-art.Optimal management of Ewing sarcoma family of tumors: recent developments in systemic therapy.Experimental research on the in vitro antitumor effects of Crataegus sanguinea.Topotecan and cyclophosphamide in adults with relapsed sarcoma.Intracardiac Low-grade Sarcoma Following Treatment for Ewing Sarcoma.Managing sarcoma: where have we come from and where are we going?The value of high-dose chemotherapy in patients with first relapsed Ewing sarcoma.Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma.Prognostic factors and clinical outcome of patients with Ewing's sarcoma family of tumors in adults: multicentric study of the Anatolian Society of Medical Oncology.Role of High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation for Children and Young Adults with Relapsed Ewing's Sarcoma: A Systematic Review.Role of High-dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed Ewing's Sarcoma: A Case Report with Focused Review of Literature.Identifying the druggable interactome of EWS-FLI1 reveals MCL-1 dependent differential sensitivities of Ewing sarcoma cells to apoptosis inducers Etoposide and carbo-or cisplatin combination therapy in refractory or relapsed Ewing sarcoma: A large retrospective study Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

P2860

Q28073218-1CD2589D-237A-45AE-8428-E40CB6678AC4 Q28085071-7C09B595-6E86-497F-AA86-436BAB4A3EEA Q33274572-05759105-97E6-4857-95E6-180213989C44 Q33404428-7A2C9433-481E-4F5E-A0B5-F4A56512789E Q33618884-98B2D2C5-AF1F-435F-808B-E7087E791BF1 Q33835657-A56C405C-04A1-4E4F-8621-D873363B8EE3 Q34136875-37130722-0E9A-47EF-A231-69456BAB5E85 Q34373180-03170A72-A320-4715-A4D0-A73654366B0B Q34787772-D7967C9F-5DCC-40C5-A5CD-F6A63273304B Q35884342-7AD5BD88-EB4E-4516-BD46-EC0BE4C6C2EB Q35957998-1ADA60EA-6DD4-4A39-AD5F-696204DB0FA6 Q35987417-E29BCCCE-ED0F-46CD-9254-8BE51896E21B Q36011879-DFE7D796-39F7-4F5E-9615-745057539FEF Q36191321-A46D08FE-9BD1-4F68-8AC8-5CB5B11D4C42 Q36508630-5305B2BB-1B1B-4B68-8B89-94608DFB0B44 Q36705188-CF3164F6-4DE3-4476-AFC6-91DCBCF2241A Q36881113-63A5A7BC-C86B-40C4-A667-F5C0B4D74FA0 Q36970948-0CC2CF77-34E2-494A-B510-481F206E77D1 Q37049291-7D5DDB16-6B1A-41DA-B95C-7BD9C966225A Q37158211-F25DEF00-5E7C-494A-8D87-7C5C028A7F2A Q37532566-73287024-BB88-4B6D-B732-A3088FBD46E9 Q37890995-0263BF53-8100-4DEE-871F-D3BCB9DC165F Q37980482-74F818E0-DAF7-4B3B-9BF5-264D2E080564 Q38113988-D187471B-78FB-4A5F-BE36-F9D8DDD2E1DB Q39191728-80B0EACB-3822-49BF-9835-457C3CDA3AAA Q40278945-B5CB70CA-5A6F-42F8-A89A-9E5A940832A2 Q40433321-3FDEF3E3-4A07-4133-A0CD-985C111DB866 Q41988197-D676D12C-BC63-440D-9D88-9A95AD6BB5FD Q43833260-1E7F22EE-F015-4D8A-B238-028FA6728B8F Q44611540-26884E8A-2D8D-40B6-B2E4-C4D5FAE3C6AE Q45969231-5AE9D1E8-3A3C-47C3-97BC-3DC91197E4CC Q55426535-A304893B-0549-4BD6-AB61-0AF56A1CBA6A Q55508881-4D55712D-05F2-42CE-876F-94A70F8235DF Q57174958-86C51EAF-AD55-4B00-A6CD-01ED69E0FF5B Q57570538-66139B9E-E6B6-4DAC-B52E-84FDFC0E3CBB Q57570627-7334549B-4210-408D-8749-318B0C8CA693

P2860

Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors.

http://www.wikidata.org/entity/Q42162649

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors.

@en

Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors.

@nl

type

label

Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors.

@en

Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors.

@nl

prefLabel

Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors.

@en

Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors.

@nl

P1433

Q42162649-DC1311BF-59E5-4169-9001-10C96ED836AA

P1476

Q42162649-5878FD60-9D98-44ED-B235-EE7C797BFF4C

P2093

Q42162649-7DE8F4C3-4348-4FF4-BC55-15EA5B6EC99D

Q42162649-85A697DF-B1D0-4C26-99F3-DBF08CBF6CF3

Q42162649-882C5E87-3E19-4CA4-AF43-534E4A63A0E4

Q42162649-BE3EC2E1-DFE0-4C59-9382-5A87622CEC7D

Q42162649-FF746279-58BF-4A82-A964-67740E513C42

P304

Q42162649-2DC6A462-1FA6-43CD-B34B-D8D62FD74DE1

P31

Q42162649-6C279056-331F-453C-AE47-BF3E64D00489

P356

Q42162649-E8A58294-9A7B-4AAA-BF08-C54BDACE0043

P433

Q42162649-5B618AFE-485F-4B50-8222-1AC08CD3D2C8

P478

Q42162649-5ABC06A2-3A9B-4B2A-95F9-A75DAEF86C38

P50

Q42162649-F0D053CE-D9CF-4A5B-9B24-DA6BE759129E

P577

Q42162649-2B4A2066-E84E-40CE-8AB8-1B46AAB183AD

P698

Q42162649-F3DE544B-6632-406E-ABF1-93CFD7BBE61E

P356

P1433

Pediatric Blood & Cancer

P1476

Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors

@en

P2093

Andrea Hunold

http://www.w3.org/2001/XMLSchema#string

Caren Liebscher

http://www.w3.org/2001/XMLSchema#string

Herbert Jürgens

http://www.w3.org/2001/XMLSchema#string

Michael Paulussen

http://www.w3.org/2001/XMLSchema#string

Nicole Weddeling

http://www.w3.org/2001/XMLSchema#string

P304

795-800

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PBC.20719

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

47

http://www.w3.org/2001/XMLSchema#string

P50

P577

2006-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16411206

http://www.w3.org/2001/XMLSchema#string